David Happel - President & CEO, Director at Sagimet Biosciences Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
President & CEO, Director
Stock Symbol
SGMT on Nasdaq
Industry
Pharmaceutical Preparations
All Insider Reports
All Insider Reports

There are no Buy or Sell transactions made by David Happel since 4/23/2024

Holdings reported by David Happel for Sagimet Biosciences Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Series A Common Stock 639K $3.37M $5.27 Mar 26, 2024 Direct
Series A Common Stock 755K $2.39M $3.17 Feb 6, 2025 Direct
Stock Option (Right to Buy) 472K Feb 6, 2025 Direct Series A Common Stock

Transactions reported by David Happel for Sagimet Biosciences Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.